VR

Van Rooijen Pharma

BE0478.869.796

Turnover
€ 4.11M ↑ 17% 2025 Total € 56.42M
Turnover growth
16.8% ↑ 16.8 pt 2025
Profit
€ 474K ↑ 34% 2025 Total € 2.73M
EBITDA
€ 645K ↑ 43% 2025 Total € 4.11M
EBITDA margin
15.7% ↑ 2.9 pt 2025
EBIT
€ 636K ↑ 35% 2025 Total € 3.90M
Net profit
€ 474K ↑ 34% 2025 Total € 2.73M
Net margin
11.5% ↑ 1.5 pt 2025
Capex
€ 10K 2025 Total € 153K
Assets
€ 1.69M ↑ 16% 2025
Equity
€ 669K ↑ 12% 2025
Debt
€ 1.02M ↑ 19% 2025
Cash
€ 0 2020
Cashflow
€ 483K ↑ 46% 2025 Total € 2.25M
Working capital
€ 634K ↑ 13% 2025
Current ratio
1.62 ↓ 2% 2025
Quick ratio
1.63 ↓ 2% 2025
Working capital ratio
1.63 ↓ 2% 2025
Debt
€ 1.02M ↑ 19% 2025
Short-term debt
€ 1.01M ↑ 19% 2025
Long-term debt
€ 0 2013
Debt / EBITDA
1.58 ↓ 17% 2025
Solvability
39.7% ↓ 1.3 pt 2025
Long term debt ratio
0.00 2013
Interest Coverage Ratio
310 ↑ 500% 2025
Gross profitability
72.1% ↑ 16.4 pt 2025
Net profitability
70.8% ↑ 11.4 pt 2025
Return On Assets (ROA)
28.11 ↑ 15% 2025
Return On Equity (ROE)
70.80 ↑ 19% 2025
Customer credit
140 ↑ 2% 2025
Supplier credit
63.00 ↑ 42% 2022
Days Sales Outstanding (DSO)
140 ↑ 2% 2025
Days Sales of Inventory (DSI)
0.00 2013
Taxes
€ 83K ↑ 147% 2025 Total € 1.30M
Salaries and Social Security Contributions
€ 82K ↑ 33% 2025 Total € 3.07M
Employees
8.80 ↓ 1% 2025
Staff cost per employee
€ 9K ↑ 34% 2025
Dividends
€ 400K ↑ 60% 2025 Total € 2.50M
Dividend payout
84.4% ↑ 13.8 pt 2025